Brugada syndrome drugs to avoid: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
{| cellspacing="2" cellpadding="3" border="0" | {| cellspacing="2" cellpadding="3" border="0" | ||
|- | |- | ||
| Generic name | | '''Generic name''' | ||
| Brand name® | | '''Brand name®''' | ||
| Class / Clinical use | | '''Class / Clinical use''' | ||
| References | | '''References''' | ||
| Recommendation | | '''Recommendation''' | ||
|- | |- | ||
| [http://www.drugbank.ca/drugs/DB01426 Ajmaline] | | [http://www.drugbank.ca/drugs/DB01426 Ajmaline] |
Revision as of 22:56, 13 October 2012
Brugada syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Brugada syndrome drugs to avoid On the Web |
American Roentgen Ray Society Images of Brugada syndrome drugs to avoid |
Risk calculators and risk factors for Brugada syndrome drugs to avoid |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The following drugs should be avoided in patients with Brugada syndrome. [1][2]
Generic name | Brand name® | Class / Clinical use | References | Recommendation |
Ajmaline | e.g. Gilurytmal® - more brand names here - |
Antiarrhythmic Agent (1A: Na-blocker) / Arrhythmias | Brugada 1997 Rolf 2003 Wolpert 2005 Bébarová 2005 |
Class I |
Flecainide | e.g. Tambocor® - more brand names here - |
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias | Krishnan 1998 Brugada 2000 Gasparini 2003 Meregalli 2006 Stokoe 2007 |
Class I |
Pilsicainide | e.g. Sunrhythm® - more brand names here - |
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias | Takenaka 1999 Fujiki 1999 Takagi 2002 Kimura 2004 |
Class I |
Procainamide | e.g. Procan® Pronestyl® - more brand names here - |
Antiarrhythmic Agent (1A: Na-blocker) / Arrhythmias | Miyazaki 1996 Brugada 1997 Joshi 2007 Villemaire 1992 |
Class I |
Propafenone | e.g. Rythmol® - more brand names here - |
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias | Matana 2000 Akdemir 2002 Hasdemir 2006 Shan 2008 Stark 1996 |
Class IIa |
Recommendation: Class I: convincing evidence/opinion; Class IIa: evidence/opinion less clear; Class IIb: conflicting evidence/opinion; Class III: very little evidence.
References
- ↑ www.brugadadrugs.org
- ↑ Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA (2009). "Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org)". Heart Rhythm : the Official Journal of the Heart Rhythm Society. 6 (9): 1335–41. doi:10.1016/j.hrthm.2009.07.002. PMC 2779019. PMID 19716089. Retrieved 2012-10-13. Unknown parameter
|month=
ignored (help)